CNNNew Alzheimer's drug aducanumab: cost, side effects, timeline and other questions answeredJun 10, 2021Jacqueline HowardBy Jacqueline Howardbookmark_bordersharemore_vert
KFFFDA’s Approval of Biogen’s New Alzheimer’s Drug Has Huge Cost Implications for Medicare and BeneficiariesJun 10, 2021Tricia Neuman & Juliette CubanskiBy Tricia Neuman & Juliette Cubanskibookmark_bordersharemore_vert
STATThird member of FDA expert committee resigns over Alzheimer's decisionJun 10, 2021Andrew JosephBy Andrew Josephbookmark_bordersharemore_vert
The Wall Street JournalFDA's Approval of Alzheimer's Drug Leads to Third Adviser's ResignationJun 10, 2021Thomas M. BurtonBy Thomas M. Burtonbookmark_bordersharemore_vert
ReutersTwo members of U.S. FDA advisory panel resign over Alzheimer's drug approvalJun 9, 2021Deena BeasleyBy Deena Beasleybookmark_bordersharemore_vert
The New York TimesThree F.D.A. Advisers Resign Over Agency's Approval of Alzheimer's Drug (Published 2021)Sep 2, 2021Pam Belluck & Rebecca RobbinsBy Pam Belluck & Rebecca Robbinsbookmark_bordersharemore_vert
CNBCThird member of prestigious FDA panel resigns over approval of Biogen's Alzheimer's drugJun 10, 2021Berkeley Lovelace & Berkeley Lovelace Jr.By Berkeley Lovelace & Berkeley Lovelace Jr.bookmark_bordersharemore_vert
Vox.comBiogen’s new Alzheimer’s drug could cost Medicare billions after FDA approvalJun 10, 2021Dylan ScottBy Dylan Scottbookmark_bordersharemore_vert
The Washington PostTwo members of an FDA advisory committee quit after approval of controversial Alzheimer's drugJun 9, 2021Laurie McGinleyBy Laurie McGinleybookmark_bordersharemore_vert
ReutersThird member of U.S. FDA advisory panel resigns over Alzheimer's drug approvalJun 11, 2021Julie Steenhuysen & Carl O'DonnellBy Julie Steenhuysen & Carl O'Donnellbookmark_bordersharemore_vert